CompanyGraph
What stands out
- Valued far above the size of its business
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $18.3M, lower than 95% of all stocks globally
- FinancialsAltman Z-Score 0.93: distress zone
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Valued far above the size of its business
Financials view
Market Capitalization
588.33MUSDvs all stocks (USD)
Revenue (TTM)
18.30MUSDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
2.14xvs all stocks
52-Week Change
-16.41%vs all stocks
Market Capitalization
588.33MUSDvs all stocks (USD)
Enterprise Value
263.75MUSDvs all stocks (USD)
Forward P/E
-5.71xvs Biotechnology peers
Price to Sales (TTM)
32.14xvs Biotechnology peers
Price to Book (MRQ)
1.95xvs Biotechnology peers
Enterprise to Revenue
14.41xvs Biotechnology peers
Enterprise to EBITDA
-3.06xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
-1677.08%vs Biotechnology peers
Return on Assets (TTM)
-19.58%vs Biotechnology peers
Return on Equity (TTM)
-37.75%vs Biotechnology peers
Revenue (TTM)
18.30MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.1000USDUpdated Sep 27, 2026Quarterly Revenue Growth
-92.40%vs Biotechnology peers
Gross Profit (TTM)
18.30MUSDvs all stocks (USD)
EBITDA (TTM)
-86.21MUSDvs all stocks (USD)
Net Income (TTM)
-82.66MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-92.40%vs Biotechnology peers
Operating Cash Flow (TTM)
-82.41MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-75.21MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 27, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
76.20MUSDFY2025 · Dec 31, 2025Operating Income
-22.36MUSDvs all stocks (USD)
Pre-tax Income
-17.13MUSDFY2025 · Dec 31, 2025Income Tax Expense
238.00KUSDFY2025 · Dec 31, 2025Net Income
-17.37MUSDFY2025 · Dec 31, 2025EBIT
-22.36MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-20.99MUSDFY2025 · Dec 31, 2025Research & Development
68.73MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
29.84MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
5.21MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-17.37MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-69.49MUSDFY2025 · Dec 31, 2025Free Cash Flow
-69.71MUSDDerived from operating cash flow minus capital expenditure. This filing charges 1.38M of depreciation against 220K of capital expenditure, and its own free-cash-flow line reads -75.81M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
14.19MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-17.37MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
1.38MUSDFY2025 · Dec 31, 2025Stock-based Compensation
6.30MUSDFY2025 · Dec 31, 2025Other Non-cash Items
4.48MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
1.09MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
221.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-65.60MUSDFY2025 · Dec 31, 2025Capital Expenditures
-220.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-192.52MUSDFY2025 · Dec 31, 2025Sale of Investments
133.00MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-59.74MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
109.64MUSDFY2025 · Dec 31, 2025Shares Outstanding
217.90MSharesUpdated Sep 27, 2026Float Shares
179.76MSharesUpdated Sep 27, 2026Shares Short
38.64MSharesUpdated Sep 27, 2026Short Ratio
11.02daysvs all stocks
Short % of Shares Outstanding
20.12%vs all stocks
% Held by Insiders
0.57%vs all stocks
% Held by Institutions
104.09%vs all stocks
Total Cash (MRQ)
330.28MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.52USDUpdated Sep 27, 2026Total Debt (MRQ)
5.70MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0189xvs Biotechnology peers
Current Ratio (MRQ)
9.36xvs Biotechnology peers
Book Value per Share (MRQ)
1.39USDUpdated Sep 27, 2026Total Assets
151.57MUSDvs all stocks (USD)
Total Current Assets
143.92MUSDFY2025 · Dec 31, 2025Total Liabilities
52.56MUSDFY2025 · Dec 31, 2025Total Non-current Assets
7.64MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
5.94MUSDFY2025 · Dec 31, 2025Total Current Liabilities
46.62MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
12.67MUSDFY2025 · Dec 31, 2025Other Short-term Investments
124.39MUSDFY2025 · Dec 31, 2025Accounts Receivable
2.01MUSDFY2025 · Dec 31, 2025Accounts Payable
1.30MUSDFY2025 · Dec 31, 2025Short-term Debt
4.24MUSDFY2025 · Dec 31, 2025Deferred Revenue
26.88MUSDFY2025 · Dec 31, 2025Long-term Debt
0.00USDFY2025 · Dec 31, 2025Other Non-current Liabilities
4.35MUSDFY2025 · Dec 31, 2025Common Stock (Book)
2.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-711.95MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
99.01MUSDvs all stocks (USD)
52-Week Low
2.66USDUpdated Sep 27, 202652-Week High
8.21USDUpdated Sep 27, 202652-Week Change
-16.41%vs all stocks
Beta
2.14xvs all stocks
50-Day MA
3.30USDUpdated Sep 27, 2026200-Day MA
4.09USDUpdated Sep 27, 2026Avg 10-Day Volume
5.56MSharesUpdated Sep 27, 2026Avg 30-Day Volume
3.90MSharesUpdated Sep 27, 2026Diluted EPS (TTM)
-0.5700USDUpdated Sep 27, 2026Other Income / Expense
28.00KUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
How does this company use capital?
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Valued far above the size of its businessSignificant
Price-to-Sales: 32.14Revenue Growth YoY: -0.92
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 9.36Altman Z-Score: 0.93
Financial Health
Altman Z-Score 0.93: distress zoneCritical
Altman Z-Score: 0.93
High structural barrier to entryNotable
Barrier to Entry: 1.36
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $18.3M, lower than 95% of all stocks globallySignificant
Revenue (USD): 18,303,000Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
OrthoPediatrics Corp.
Tier 1ProductionApproval-Gated PipelineRule
Tibet Weixinkang Medicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Aquestive Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Sihuan Bioengineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Phathom Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shandong Wohua Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
SS Innovations International, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Gkht Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hainan Shuangcheng Pharmaceuticals Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Yatai Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
ChemPartner Pharmatech Co., Ltd.
2 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityIndustry-Benchmarked Return on Capital Elevated
TV Tokyo Holdings Corporation
2 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityIndustry-Benchmarked Return on Capital Elevated
Tactile Systems Technology Inc.
2 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityIndustry-Benchmarked Return on Capital Elevated